Table 1. TEAE onset, dose adjustment, discontinuation due to a TEAE, recovery status, and final perampanel dose for patients reporting TEAEs of dizziness, somnolence, and/or headache during the Titration Period (Safety Analysis Set)

					Recovery Status by TEAE event[a]				
	TEAE onset week Mode (range)	**Dose at the time of the TEAE Mode (range)**	**Dose adjustment due to the TEAE, n (%)**	**TEAE resulted in discontinuation n (%)**		**In Recovery (Events [%])**	**Recovered (Events [%])**	**Not Recovered (Events [%])**	**Final perampanel dose (mg/day) (maintenance) Mode (range)**
Dizziness (pts, n=48)	5 (1, 12)	4 (2, 10)	13 (27.1)	9 (18.8)	**Dizziness (events, n=50)**	3 (60.0)	46 (92.0%)[b]	1 (2.0)	4 (2, 10)
Somnolence (pts, n=9)	3 (1, 7)	4 (2, 8)	2 (22.2)	0 (0.0)	**Somnolence (events, n=9)**	1 (11.1)	8 (88.9%)	0 (0.0)	6 (8, 4)
Headache (pts, n=6)	1 (1,9)	2 (2, 4)	1 (16.7)	2 (33.3)	**Headache (events, n=6)**	0 (0.0)	6 (100.0)	0 (0.0)	4 (2,6)

[a]Numbers and percentages for recovery are based on the number of events (n=50). The percentages are calculated from number of events for that TEAE. [b]Includes two patients who each had 2 events of dizziness during titration.

TEAE, treatment-emergent adverse event; pts, patients